Écrit par Pluristem | 23 Juillet 2012

HAIFA, ISRAEL, July 18, 2012 -- Pluristem Therapeutics, Inc. (NASDAQ:PSTI; TASE: PLTR), today announced that in anticipation of initiating a Phase II study using PLX-PAD cells for the treatment of Intermittent Claudication (IC), the company has recently entered into a collaborative agreement with CPC Clinical Research (CPC) for services related to enrolling and sustaining clinical sites...

Écrit par Globaldata | 19 Juillet 2012

LONDON, UK (GlobalData), 18 July 2012 - GlaxoSmithKline (GSK), the British pharmaceutical giant, acquired Human Genome Sciences (HGS) on Monday, July 16, 2012 for $14.25/share. On an equity basis this deal was worth about $3.6 billion; however, the final deal size was approximately $3 billion net of cash and debt. GSK paid a premium of 99% from when it offered its initial private...

Écrit par GBI | 16 Juillet 2012

NEW YORK (GBI Research), 13 July 2012 - Biobetters, drugs that have been improved since their initial incarnations, are demonstrating fantastic growth and leaving their originators well behind, states new research by pharmaceutical business specialists GBI Research.

The new report* explains how the more advanced drugs are far outstripping their biologic predecessors in terms of sales and...

Écrit par Quadro | 13 Juillet 2012

The Quadro Ytron® HV-Emulsifier Group Seri

Waterloo, Canada, July 11, 2012 - Size Reduction or Milling of APIs (Active Pharmaceutical Ingredients) is a key step in the drug development process. When milling an API, the developer requires a tight particle size distribution that ensures consistent drug substance and drug product quality. Traditionally, dry milling technologies such as...